Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Published:2023-10 Issue: Volume: Page:
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Veverka Karen A.,Thng Steven T.G.,Silverberg Jonathan I.,Armstrong April W.,Menezes Josemund,Kaoukhov Alexandre,Blauvelt Andrew^ORCID

Publisher

Elsevier BV

Subject

Dermatology

Reference20 articles.

1. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies;Brunner;J Allergy Clin Immunol,2017

2. The challenge of managing atopic dermatitis in the United States;Feldman;Am Health Drug Benefits,2019

3. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II;Wollenberg;J Eur Acad Dermatol Venereol,2018

4. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis;Simpson;N Engl J Med,2016

5. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis;Beck;N Engl J Med,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atopic dermatitis and IgE-mediated food allergy;Annals of Allergy, Asthma & Immunology;2024-09

2. Emerging Systemic Treatment Options in Atopic Dermatitis;Balkan Medical Journal;2024-07-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP